Fundz

Watching Keros Therapeutics, Inc.? See every signal: funding, hires, M&A, contracts, sentiment.

Book a demoChoose your plan
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →
Back to SEC Filings
Executive ChangeItem 5.02 · 8-KLOW RiskNeutral

Keros Therapeutics, Inc.

kerostx.com
Filed: Jul 17, 2026LexingtonCIK: 0001664710Biotechnology
Full company profileView on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

Keros Therapeutics announced the voluntary resignation of CFO Keith Regnante effective August 3, 2026, and appointed Annita Tanini, the Corporate Controller and Vice President of Finance, as interim principal financial officer effective August 4, 2026. The departure was amicable with no accounting or financial reporting disagreements, indicating a smooth leadership transition.

Key Takeaways

Keith Regnante resigned voluntarily as CFO to pursue other opportunities, with departure effective August 3, 2026

Annita Tanini, previously Corporate Controller and Vice President of Finance, appointed as interim principal financial officer and principal accounting officer effective August 4, 2026

2 more takeaways

Filing Overview

Form Type8-K
Filing DateJul 17, 2026
Item5.02
CategoryExecutive Change
CIK0001664710
Accession #0001664710-26-000063
Risk LevelLOW
SentimentNeutral
Signalinformational
Topics
executive departureleadership transition

What This Means

A senior executive (CEO, CFO, etc.) has joined, departed, or changed roles. Leadership changes can significantly impact strategy.
View Full Filing on SEC.govBrowse More Filings

Keros Therapeutics, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.